China Pharma subsidiary acquires psoriasis patent for $1.5M in stock

CHINA PHARMA HOLDINGS, INC.

Helpson, a wholly owned subsidiary of China Pharma, entered a Technology Transfer Agreement with Lihua Li to acquire an invention patent for a psoriasis treatment.
Total consideration is $1.5 million, paid via 15 million restricted shares of common stock at $0.10 per share to the transferor and two designees.
If the product launches and generates profit within 10 years, Helpson will pay 10% of annual net profit in cash to the transferor.
Shares will be issued in an offshore transaction exempt from registration under Regulation S of the Securities Act.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

CHINA PHARMA HOLDINGS, INC. entered into Technology Transfer Agreement with Lihua Li valued at $1.50 million (effective 2024-02-02).

Action: entry
Agreement: license
Counterparty: Lihua Li
Value: $1.50 million
Effective: 2024-02-02

Exact text from the filing

ntered into a Technology Transfer Agreement (the “ Agreement ”) with Lihua Li (the “ Transferor ”). The Transferor owns an invention patent of a pharmaceutical composition for treatment of psoriasis (the “ Invention Patent ”).

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

CHINA PHARMA HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-24-011587

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.